In contrast, treatment with anti-TIM4 administered before or after the onset of CIA significantly inhibited the development and progression of CIA by reducing proinflammatory cytokines without affecting T or B-cell responses, suggesting that anti-TIM4 treatment may be a suitable target for the treatment of RA (50). This evidence concerns the gene TIMD4 and rheumatoid arthritis.